Pieris Pharmaceuticals (FRA:PI60) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pieris Pharmaceuticals Debt-to-Equity?

Pieris Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Pieris Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Pieris Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €20.21 Mil. Pieris Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pieris Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:PI60' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.34 Max: 0.85
Current: 0.56

During the past 11 years, the highest Debt-to-Equity Ratio of Pieris Pharmaceuticals was 0.85. The lowest was 0.07. And the median was 0.34.

FRA:PI60's Debt-to-Equity is ranked worse than
76.71% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:PI60: 0.56

Pieris Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Pieris Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals Debt-to-Equity Chart

Pieris Pharmaceuticals Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.32

0.55

0.29

0.47

Pieris Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.85	0.32	0.40	-	-

Competitive Comparison of Pieris Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Pieris Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pieris Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Debt-to-Equity falls into.

Pieris Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pieris Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	24.537
	=	0.00

Pieris Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	20.207
	=	0.00

Pieris Pharmaceuticals (FRA:PI60) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pieris Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals (FRA:PI60) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (FRA:PI60) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PIRS:USA PI6:Germany

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Pieris Pharmaceuticals (FRA:PI60) Headlines

No Headlines